Terminated PHASE3 INTERVENTIONAL 3-arm NCT02945046

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Epidosic Cluster Headache

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Conditions Episodic Cluster Headache

Interventions Fremanezumab Placebo

Updated 28 times since 2017 Last updated: Nov 6, 2021 Started: Jan 19, 2017 Primary completion: May 13, 2019 Completion: May 13, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was terminated as a result of a pre-specified futility analysis at the interim of 150 participants completing the efficacy analysis of the study.

Other terminated trials from Teva Branded Pharmaceutical Products R&D, Inc.

More terminations from Teva Branded Pharmaceutical Products R&D, Inc.

This PHASE3 trial investigates Episodic Cluster Headache and is currently terminated or withdrawn. Teva Branded Pharmaceutical Products R&D, Inc. leads this study, which shows 28 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

28 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 23 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Aug 2020 — Nov 2020 [monthly]

Terminated PHASE3
May 2020 — Aug 2020 [monthly]

Terminated PHASE3
Mar 2020 — May 2020 [monthly]

Terminated PHASE3
Feb 2020 — Mar 2020 [monthly]

Terminated PHASE3
Jan 2020 — Feb 2020 [monthly]

Terminated PHASE3

Status: Completed → Terminated
Dec 2019 — Jan 2020 [monthly]

Completed PHASE3

Status: Terminated → Completed
Nov 2019 — Dec 2019 [monthly]

Terminated PHASE3
Oct 2019 — Nov 2019 [monthly]

Terminated PHASE3
Sep 2019 — Oct 2019 [monthly]

Terminated PHASE3
Aug 2019 — Sep 2019 [monthly]

Terminated PHASE3
Jul 2019 — Aug 2019 [monthly]

Terminated PHASE3

Status: Recruiting → Terminated
Apr 2019 — Jul 2019 [monthly]

Recruiting PHASE3
Jan 2019 — Apr 2019 [monthly]

Recruiting PHASE3
Oct 2018 — Jan 2019 [monthly]

Recruiting PHASE3
Jul 2018 — Oct 2018 [monthly]

Recruiting PHASE3
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE3
Oct 2017 — Jun 2018 [monthly]

Recruiting PHASE3
Sep 2017 — Oct 2017 [monthly]

Recruiting PHASE3
Jun 2017 — Sep 2017 [monthly]

Recruiting PHASE3
Apr 2017 — Jun 2017 [monthly]

Recruiting PHASE3
Feb 2017 — Apr 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Teva Branded Pharmaceutical Products R&D, Inc.

Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Amherst, United States , Ann Arbor, United States , Ashkelon, Israel , Auchenflower, Australia , Aurora, United States , Berlin, Germany , Bialystok, Poland , Bochum, Germany , Calgary, Canada and 67 more locations